Walker, MD Saint Francis Medical Center NASS Patient Safety Committee Member Cape Girardeau, MO Introduction and Mechanism of Action Glucagon-like peptide-1 (GLP-1) agonists are recognized for their efficacy in managing diabetes mellitus and aiding weight loss.1 They also reduce cardiovascular risk.2,3,4 The mechanism of action involves mimicking GLP-1, an incretin hormone that enhances insulin secretion after an oral glucose load.5,6 Beyond these effects, GLP-1 agonists are involved in inhibiting glucagon secretion, thus stabilizing blood glucose levels
The lack of commonly available and sufficiently selective antibodies to detect GIPR further remains a notable limitation that hinders in-depth immunohistochemical analysis of GIPR in the brain
With its beaded skin, lumbering gait, and tendency to hide out in the heat of the day, the Gila monster doesnt exactly scream medical breakthrough. But behind that prehistoric glare is a biological secret that changed how we treat type 2 diabetes and obesity
The human body is susceptible to many forms of infections and illnesses more so during intense activity
Lavorgna, M
Obesity & Weight Regulation Research Tirzepatide has demonstrated robust, dosedependent weight loss in clinical and preclinical models
